T 2571/18 (Abiraterone and prednisone combination against prostate cancer/JANSSEN) of 14.08.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T257118.20200814
- Date of decision
- 14 August 2020
- Case number
- T 2571/18
- Petition for review of
- -
- Application number
- 12160586.9
- IPC class
- A61K 45/06A61K 31/58A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods and compositions for treating cancer
- Applicant name
- Janssen Oncology, Inc.
- Opponent name
- -
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 83 (2007)European Patent Convention Art 87(1) (2007)
- Keywords
- Priority - basis in priority document (yes)
Sufficiency of disclosure - (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division for further prosecution based on the main request filed as auxiliary request 9 by letter dated 24 July 2020.